Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
3.260
-0.030 (-0.91%)
Jul 14, 2026, 12:32 PM EDT - Market open
Elicio Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 14.95 | 18.56 | 17.62 | 12.89 | 6.16 | 88.76 |
Cash & Short-Term Investments | 14.95 | 18.56 | 17.62 | 12.89 | 6.16 | 88.76 |
Cash Growth | -18.54% | 5.36% | 36.64% | 109.45% | -93.06% | 156.47% |
Other Receivables | - | - | - | - | - | 0.81 |
Total Trade Receivables | - | - | - | - | - | 0.81 |
Other Current Assets | 1.25 | 0.75 | 3.08 | 3.45 | 4.56 | 1.69 |
Total Current Assets | 16.2 | 19.31 | 20.69 | 16.35 | 10.72 | 91.25 |
Net Property, Plant & Equipment | 4.79 | 5.08 | 6.19 | 7.28 | 8.5 | 4.44 |
Long-Term Investments | - | - | - | - | - | 0.72 |
Other Long-Term Assets | 1.7 | 1.47 | 1.3 | 3.52 | 3.45 | 0.11 |
Total Assets | 22.69 | 25.86 | 28.18 | 27.15 | 22.66 | 96.51 |
Accounts Payable | 0.27 | 0.67 | 1.04 | 4.37 | 2.81 | 4.71 |
Accrued Expenses | 5.92 | 6.43 | 8.42 | 3.76 | 1.94 | 3.22 |
Current Portion of Leases | 1.04 | 1.01 | 0.9 | 0.91 | 0.69 | 0.89 |
Unearned Revenue | - | - | 1.17 | 0.69 | 1.44 | 2.3 |
Other Current Liabilities | 3.6 | 2.62 | 2.83 | 0.04 | - | 0.17 |
Total Current Liabilities | 7.23 | 8.11 | 11.52 | 9.76 | 6.87 | 11.3 |
Long-Term Debt | 9.48 | 9.41 | 20.03 | - | - | - |
Long-Term Leases | 3.82 | 4.09 | 5.11 | 6.01 | 6.79 | 3.48 |
Other Long-Term Liabilities | - | - | - | - | 0.09 | 0.24 |
Total Long-Term Liabilities | 13.3 | 13.5 | 25.14 | 6.01 | 6.88 | 3.71 |
Total Liabilities | 24.13 | 24.23 | 39.49 | 15.77 | 13.75 | 15.01 |
Common Stock | 0.19 | 0.18 | 0.11 | 0.1 | 0 | 0.3 |
Treasury Stock | -0.15 | -0.15 | -0.15 | -0.15 | - | - |
Additional Paid-in Capital | 244.14 | 235.41 | 183 | 153.83 | 4.86 | 296.45 |
Accumulated Other Comprehensive Income | -0.12 | -0.13 | -0.18 | -0.2 | - | -0.1 |
Retained Earnings | -245.5 | -233.67 | -194.1 | -142.2 | -107.01 | -215.14 |
Total Common Shareholders' Equity | -1.44 | 1.64 | -11.31 | 11.37 | -102.15 | 81.51 |
Minority Interest | - | - | - | - | 111.06 | - |
Shareholders' Equity | -1.44 | 1.64 | -11.31 | 11.37 | 8.92 | 81.51 |
Total Liabilities & Equity | 22.69 | 25.86 | 28.18 | 27.15 | 22.66 | 96.51 |
Total Debt | 14.34 | 14.51 | 26.04 | 6.92 | 7.48 | 4.37 |
Net Cash (Debt) | 0.61 | 4.05 | -8.42 | 5.98 | -1.33 | 84.39 |
Net Cash Growth | -84.99% | - | - | - | - | - |
Net Cash Per Share | 0.04 | 0.27 | -0.69 | 1.18 | -0.90 | 57.16 |
Book Value | -1.44 | 1.64 | -11.31 | 11.37 | -102.15 | 81.51 |
Book Value Per Share | -0.09 | 0.11 | -0.93 | 2.25 | -69.19 | 55.21 |
Tangible Book Value | -1.44 | 1.64 | -11.31 | 11.37 | -102.15 | 81.51 |
Tangible Book Value Per Share | -0.09 | 0.11 | -0.93 | 2.25 | -69.19 | 55.21 |